Asset profile
Bepranemab
Monoclonal antibody
Evidence outlook · results not reported
NCT04867616 · Alzheimer's Disease
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT04867616: The study randomized 466 participants to two bepranemab dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in CDR-SB at Week 80, but whether this endpoint was met cannot be determined because results are not posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Bepranemab: this drug | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| NIO752 | Phase 3 | RNA / oligonucleotide | Tau (monoclonal antibody) | ||
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| AADvac1 | Phase 2 | Vaccine | Tau (monoclonal antibody) | ||
| BMS-986446 | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| ACI-35.030 | Phase 1/2 | Vaccine | Tau (monoclonal antibody) | ||
| VY7523 | Phase 1/2 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| APNmAb005 | Phase 1 | Monoclonal antibody | Tau (monoclonal antibody) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
December 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.